Objective-To assess whether angiotensin converting enzyme inhibition reduces proteinuria in diabetic nephropathy more than blood pressure reduction with other antihypertensive treatment.
Introduction
Renal failure is the main cause of death in type I (insulin dependent) diabetic patients who have nephropathy.' The deterioration in kidney function is accelerated by the hypertension that usually accompanies the kidney disease. Pharmacological reduction of raised blood pressure is today the most powerful intervention to preserve kidney function.2 It is not known with certainty, however, whether all antihypertensive drugs are equal in this respect, although angiotensin converting enzyme inhibitors may offer superior protection of renal function.'
To examine this issue further, we randomised 40 patients with diabetic nephropathy to treatment with either the angiotensin converting enzyme inhibitor enalapril or the 13l selective blocker metoprolol. The aim was to achieve the same blood pressure levels in both groups and compare the effect of the two treatments on proteinuria and on kidney function in the long term. We report the effect of the first two months of treatment.
Patients and methods
Forty patients with type I diabetes and nephropathy were studied. The patients were required to have type I diabetes, diabetic nephropathy, reduced renal function, and other diabetic complications such as retinopathy. They had a mean age of 42 (range 21-58) years and mean onset of diabetes at 17 (3-39) years of age. The mean duration of diabetes was 25 years. All patients had retinopathy, and three patients were blind. The onset and development of the kidney disease had to be typical of diabetic nephropathy. If there was any suspicion of other renal disease then kidney biopsy was performed. This was done in four patients showing diabetic nephropathy only. Presence of hypertension was not an inclusion criteria, but only two patients were not being treated for hypertension before the study. The glomerular filtration rate was lower than our age adjusted normal value' but higher than 24ml/min/1 73 m2.
Twenty two patients were randomised to enalapril and 18 to metoprolol. The initial goal was to include 60 patients but because previous treatment with angiotensin converting enzyme inhibitor was a criterion for exclusion there was a diminishing number of eligible patients in the participating centres owing to the increasing popularity of these drugs. The inclusion of new patients was therefore stopped after two years and 40 subjects. The study was performed after the patients' informed consent and approval by the local ethical committee had been obtained.
TREATMENT
Two weeks before the study, previous antihypertensive treatment was stopped except for frusemide. If this was considered unsafe, medication could be continued until two days before randomisation. The randomisation into two groups was done separately in the three centres and was stratified in three subgroups depending on renal function to ensure balance in this respect. On the day of the randomisation the patients received 5 BMJ VOLUME 300the difference between systolic and diastolic blood pressure and is shown as the mean of standing and supine values unless otherwise stated.
Urinary protein excretion was measured in 24 hour collections of urine with the biuret method. Albumin excretion was measured by immunochemical turbidometric assay, electrophoresis, or immunoprecipitation assay, depending on the hospital. Plasma renin activity was measured by radioimmunoassav. The reference range in a group of healthy people was 0-2-12 nmol/l/h. The glomerular filtration rate was measured before the study as the rate of disappearance of chromium-S1 edetic acid in plasma after a single injection.
STATISTICS
Results are presented as means (SD or range) except urinary albumin and protein excretion, serum creatinine concentration, and plasma renin activity, which are expressed as geometric means (antilog 95% confidence interval of the logarithms). Student's two tailed t test for paired and unpaired comparisons was used. Urinary albumin and protein excretion, serum creatinine concentration, and plasma renin activity were analysed after log transformation because of the skewed distributions, and significance was taken as p<0 05. Multiple linear regression analysis was used to determine the influence of mean arterial pressure and type of treatment on change in urinary albumin and protein excretion, which was fairly normally distributed, and on absolute values of urinary protein and albumin after log transformation. In addition, a sliding mean value method was used to describe the relation between blood pressure and urinary albumin and protein excretion. All urinary protein and albumin values were ranked according to the mean arterial pressure measured at the same time. A geometric mean was calculated on both albuminuria and proteinuria values for ranked measurements [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and the mean of the corresponding mean arterial pressures was calculated; then calculations were made on ranked measurements 2-20, and so on. The successive points were joined to form curves for the enalapril and the metoprolol patients (see fig 2) . The 
BLOOD PRESSURES
After the first dose the blood pressure fell in both groups to the same extent. During eight weeks' treatment similar blood pressure levels were obtained in both groups (table, fig 1) . Systolic blood pressure was significantly reduced at eight weeks in the group given metoprolol (fig 1; p<0 01 ). In the group given enalapril both the systolic and diastolic blood pressure was significantly reduced throughout. There were no significant differences in blood pressure between the groups.
The reduction in blood pressure compared with baseline was significantly higher in the patients given enalapril as they had had slightly higher blood pressure before randomisation than the patients given metoprolol. The fall in orthostatic blood pressure during treatment tended to be smaller in the patients given enalapril. Four hours after the first dose was given the mean arterial pressure fell a mean of 7 (12) Laboratory values-The glomerular filtration rate before the study was 48 (15)ml/min/1 73 m in the patients given metoprolol and 46 (14) ml/min/1 73 m in those given enalapril. Serum creatinine concentrations increased slightly but significantly in the patients given enalapril but not in those given metoprolol (table). Serum potassium rose after enalapril was given. There was no change in haemoglobin Al( concentration in either group. The baseline plasma renin activity was significantly higher in patients than in healthy controls (p<0-01), and increased in the group given enalapril and decreased in the group given metoprolol.
Discussion
This study showed that proteinuria and albuminuria could be reduced by two months' treatment with enalapril to less than half the values obtained in a control group treated with metoprolol. As expected, higher blood pressure was linked to more proteinuria. The blood pressure was similar in both groups, and it is likely that the lower level of proteinuria during treatment with enalapril is produced by a mechanism independent of systemic blood pressure. This pressure independent effect is shown in figure 2 . It seems plausible that this is an effect of changes in the renal haemodynamics caused by these drugs. Angiotensin converting enzyme inhibitors can induce and increase in renal blood flow without a concomitant reduction in glomerular filtration rate in this category of patients.' This leads to a decrease in filtration fraction, which probably reflects a lowering of glomerular filtration pressure.
Reduction of blood pressure with different antihypertensive drugs in patients with incipient or overt diabetic nephropathy leads to a reduction in urinary protein excretion.268 Treatment with an angiotensin converting enzyme inhibitor usually9' but not alwavs' 120 results in reduced proteinuria in these patients. The experimental design in these studies, however, failed to distinguish between the effect of blood pressure reduction itself and other effects of angiotensin converting enzyme inhibitors; no control groups given other types of antihypertensive treatment were used.
Insua et al, however, made this comparison and investigated the effect on microalbuminuria of six weeks' treatment with captopril in eight type I diabetic patients and of nifedipine in seven and found that captopril reduced but nifedipine increased microalbuminuria. 7 In the present study the reduction in blood pressure in the patients given enalapril was somewhat greater than in those given metoprolol owing to a tendency to higher blood pressure before the study in those given enalapril. The blood pressure was comparable in both groups during treatment, so this is unlikely to explain the difference in level ofproteinuria. During treatment, both blood pressure and treatment with enalapril had a BMJ VOLUME 300 7 APRIL 1990significant influence on the degree of proteinuira, as shown in figure 2 . There was no correlation between the fall in blood pressure and the reduction in proteinuria in either group or in the whole study population. The mean supine and standing blood pressure was best correlated with proteinuria and may therefore reflect the blood pressure throughout the day more accurately than either supine or standing blood pressure.
Although the blood pressure was similar for both treatments a tendency to higher supine and lower standing blood pressure was found in the group given metoprolol. When this was calculated as the orthostatic fall in blood pressure, there was a trend towards more orthostatic hypotension in the group given metoprolol, and this difference was significant after the first test dose and after one week. Enalapril therefore offers an advantage in this respect in these patients, who are prone to orthostatic hypotension. Enalapril was well tolerated, but two patients given metoprolol had side effects severe enough to require withdrawal of metoprolol.
The group given enalapril showed a small increase in serum creatinine concentration. If this represents a true fall in glomerular filtration rate the reduction is too small to explain the 56% reduction in albuminuria in this group. For unknown reasons there was a transient increase in serum potassium concentration in the group given metoprolol at four weeks. In the group given enalapril serum potassium concentration rose at eight weeks, although this increase was moderate and did not necessitate change of treatment in any patient. However, this supports the conclusion that angiotensin converting enzyme inhibitors should be used in these patients only after treatment with a diuretic, to ensure that they do not develop hyporeninaemic hypoaldosteronism, which could aggravate hyperkalaemia. It has been argued that diuretic treatment might increase proteinuria and worsen the prognosis in diabetic nephropathy,26 but this fear does not seem warranted because the lowest rate of deterioration so far reported in diabetic nephropathy is during treatment with a combination of antihypertensive drugs including high doses of frusemide.2 It can also be speculated that the antiproteinuric effect of enalapril might have been smaller without pretreatment with a diuretic. 23 It is uncertain whether reducing proteinuria will benefit the kidneys in the long term, but it seems logical to assume that this antiproteinuric effect reflects a beneficial effect on mechanisms harmful to the kidneys. In addition, proteinuria, irrespective oforigin, has been claimed to perpetuate the process of glomerulosclerosis.
Our results points to the conclusion that angiotensin converting enzyme inhibitors reduce proteinuria in diabetic nephropathy by a mechanism independent of the effect on systemic blood pressure. Whether the specific renal effects of angiotensin converting enzyme inhibitors lead to better preservation of kidney function, as indicated in our previous report,' has to be verified by long term studies. 
